VHL and hemangioblastoma: At the moment, Belzutifan, an oral HIF-2α inhibitor, is the only one approved by the FDA to treat VHL-associated renal cell carcinoma, hemangioblastomas, and pancreatic and neuroendocrine tumors [70].